KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Operating Expenses: 2014-2025

Historic Other Operating Expenses for Xenon Pharmaceuticals (XENE) over the last 2 years, with Sep 2025 value amounting to -$6.7 million.

  • Xenon Pharmaceuticals' Other Operating Expenses fell 47.36% to -$6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.8 million, marking a year-over-year decrease of 161.13%. This contributed to the annual value of -$20.7 million for FY2024, which is 43.69% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Other Operating Expenses stood at -$6.7 million for Q3 2025, which was down 11.66% from -$6.0 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Other Operating Expenses' 5-year high stood at -$4.6 million during Q3 2024, with a 5-year trough of -$6.7 million in Q3 2025.
  • Over the past 2 years, Xenon Pharmaceuticals' median Other Operating Expenses value was -$5.5 million (recorded in 2024), while the average stood at -$5.6 million.
  • Data for Xenon Pharmaceuticals' Other Operating Expenses shows a maximum YoY slumped of 47.36% (in 2025) over the last 5 years.
  • Over the past 2 years, Xenon Pharmaceuticals' Other Operating Expenses (Quarterly) stood at -$5.5 million in 2024, then slumped by 47.36% to -$6.7 million in 2025.
  • Its Other Operating Expenses was -$6.7 million in Q3 2025, compared to -$6.0 million in Q2 2025 and -$5.5 million in Q1 2025.